TyG-BMI Index Predicts Higher Mortality Risk in Osteoporosis Patients: Study

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-10-29 15:30 GMT   |   Update On 2025-10-29 15:30 GMT
Advertisement

Researchers have found in a new study that elevated triglyceride-glucose body mass index (TyG-BMI) levels have a strong correlation with higher risks of all-cause and cardiovascular mortality in osteoporotic patients, suggesting that insulin resistance plays an important part in their long-term outcome. Osteoporosis, a systemic skeletal disease characterized by decreased bone mass and fragility, is increasingly being seen as a disease with metabolic and cardiovascular determinants. The study was published in Frontiers in Endocrinology by Yuhao Li. and colleagues.

Advertisement

This prospective cohort consisted of 302 osteoporotic patients enrolled from 2018 to 2020 and followed up to 2024. A total of 64 all-cause deaths and 19 cardiovascular deaths were registered during follow-up. The association between TyG-BMI and mortality outcomes was assessed using restricted cubic spline and multivariable Cox proportional hazards regression analyses by researchers.

For enhancing the analysis, comparative evaluation was carried out with other IR-associated indices like TyG (triglyceride-glucose index), METS-IR (Metabolic Score for Insulin Resistance), and TG/HDL-C (triglyceride-to-high-density lipoprotein cholesterol ratio). Subgroup analysis was also carried out to determine patient subgroups at high risk, analyzing parameters like HDL levels, serum calcium, and creatinine levels.

Results

  • The results indicated a strong positive correlation between TyG-BMI and all-cause and cardiovascular mortality in osteoporotic patients.

  • For each 1-unit rise in TyG-BMI, the hazard ratio (HR) for all-cause death was 1.01 (95% CI: 1.00–1.02), proving a linear association.

  • After quartile division of participants, those in Q4 had nearly 2.8-fold increased risk of all-cause mortality compared to Q1 (HR = 2.79, 95% CI: 1.16–6.73).

  • The correlation with cardiovascular mortality was more significant—patients in Q4 demonstrated a 6.33-fold increased risk (HR = 6.33, 95% CI: 1.19–33.80) relative to Q1.

  • Additionally, ROC curve analysis and DeLong tests revealed that TyG-BMI was more superior than other insulin resistance indicators (TyG, METS-IR, TG/HDL-C) in the prediction of both all-cause and cardiovascular death.

  • Subgroup analyses revealed that cardiovascular death risk was especially high in patients with low HDL, high serum calcium, and elevated creatinine, indicating that metabolic and renal impairments can exacerbate the detrimental effects of IR in osteoporosis.

In conclusion, this prospective cohort study evidences TyG-BMI as being linearly and independently related to all-cause and cardiovascular mortality in osteoporotic patients. The results substantiated that insulin resistance is a key player in osteoporosis development and mortality, making TyG-BMI an important biomarker to determine patients at highest risk.

Reference:

Li, Y., Xie, X., Liu, Y., Sun, H., Gong, Z., & Ding, W. (2025). Association between triglyceride glucose-body mass index with all-cause and cardiovascular mortality in adults with osteoporosis: a prospective study. Frontiers in Endocrinology, 16(1649964). https://doi.org/10.3389/fendo.2025.1649964


Tags:    
Article Source : Frontiers in Endocrinology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News